Fresenius Medical Care AG & Co. KGaA to Post Q2 2023 Earnings of $0.26 Per Share, Zacks Research Forecasts (NYSE:FMS)

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) – Investment analysts at Zacks Research lowered their Q2 2023 EPS estimates for shares of Fresenius Medical Care AG & Co. KGaA in a research note issued on Tuesday, May 23rd. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings per share of $0.26 for the quarter, down from their previous forecast of $0.28. The consensus estimate for Fresenius Medical Care AG & Co. KGaA’s current full-year earnings is $1.15 per share. Zacks Research also issued estimates for Fresenius Medical Care AG & Co. KGaA’s Q3 2023 earnings at $0.28 EPS, FY2023 earnings at $1.14 EPS, FY2024 earnings at $1.46 EPS, Q1 2025 earnings at $0.32 EPS and FY2025 earnings at $1.66 EPS.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last announced its quarterly earnings data on Tuesday, February 21st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.22. The company had revenue of $5.10 billion during the quarter, compared to analyst estimates of $4.85 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.06% and a return on equity of 5.44%.

Several other research analysts have also commented on FMS. HSBC lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “reduce” rating in a report on Tuesday, March 7th. StockNews.com began coverage on shares of Fresenius Medical Care AG & Co. KGaA in a report on Thursday, May 18th. They issued a “buy” rating for the company. Truist Financial lifted their price target on shares of Fresenius Medical Care AG & Co. KGaA from $22.00 to $24.00 and gave the company a “hold” rating in a report on Thursday, April 13th. Sanford C. Bernstein began coverage on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, March 7th. They issued a “market perform” rating for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.45.

Fresenius Medical Care AG & Co. KGaA Trading Down 1.6 %

NYSE FMS opened at $21.83 on Thursday. Fresenius Medical Care AG & Co. KGaA has a one year low of $12.78 and a one year high of $30.63. The company has a 50-day simple moving average of $22.35 and a 200-day simple moving average of $19.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market capitalization of $12.81 billion, a PE ratio of 20.59 and a beta of 1.01.

Fresenius Medical Care AG & Co. KGaA Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 1st. Shareholders of record on Thursday, May 18th will be given a dividend of $0.7086 per share. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a dividend yield of 2.1%. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio (DPR) is 39.62%.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently made changes to their positions in FMS. Sandy Spring Bank bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth about $27,000. Clear Street Markets LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth about $28,000. American National Bank bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 1st quarter worth about $32,000. Assetmark Inc. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 61.1% during the 1st quarter. Assetmark Inc. now owns 1,969 shares of the company’s stock worth $42,000 after buying an additional 747 shares in the last quarter. Finally, Ronald Blue Trust Inc. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 1,156.0% during the 4th quarter. Ronald Blue Trust Inc. now owns 3,366 shares of the company’s stock worth $48,000 after buying an additional 3,098 shares in the last quarter. 5.56% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get Rating)

Fresenius Medical Care AG & Co KgaA engages in the provision of products and services for individuals with renal diseases of which regularly undergo dialysis treatment. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management.